Laurus Labs (LAURUSLABS) Panoramica del titolo
Laurus Labs Limited, insieme alle sue controllate, produce e vende farmaci e ingredienti farmaceutici attivi (API) in India e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 4/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 2/6 |
LAURUSLABS Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Laurus Labs Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹1,351.00 |
| Massimo di 52 settimane | ₹1,373.90 |
| Minimo di 52 settimane | ₹584.50 |
| Beta | 0.35 |
| Variazione di 1 mese | 21.24% |
| Variazione a 3 mesi | 32.58% |
| Variazione di 1 anno | 128.73% |
| Variazione a 3 anni | 305.22% |
| Variazione a 5 anni | 159.51% |
| Variazione dall'IPO | 1,306.12% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Aggiornamento della narrazione • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.Recent updates
Aggiornamento della narrazione • Apr 30
LAURUSLABS: Upcoming Dividend Decision And Stable Assumptions Will Support Future Upside
Analysts have kept the Laurus Labs fair value estimate unchanged at ₹1,270, with small tweaks to revenue growth, profit margin and P/E assumptions. These reflect updated models rather than a shift in overall conviction.Aggiornamento della narrazione • Apr 15
LAURUSLABS: Stronger Fundamentals And Upcoming Board Decisions Will Support Upside
Analysts have slightly reduced the Laurus Labs fair value estimate to ₹1,270 from ₹1,280 after updating assumptions on revenue growth, margins, and future P/E, while keeping the overall risk profile unchanged. Analyst Commentary Recent Street research on a different company, Laureate Education, still gives you a sense of how bullish analysts may think when they see improving fundamentals, supportive macro factors, or cleaner execution.
Aggiornamento della narrazione • Apr 01
LAURUSLABS: Currency And Execution Uncertainties Will Likely Cap Margin Upside
Analysts have made a small upward tweak to the Laurus Labs fair value estimate, with the price target moving from ₹540.28 to ₹543.09. This reflects updated assumptions on revenue growth and profitability.Aggiornamento della narrazione • Mar 18
LAURUSLABS: Higher Margin Assumptions Will Likely Struggle Against Execution Risks
Narrative Update on Laurus Labs The updated analyst price target for Laurus Labs moves from about ₹330 to roughly ₹540. Analysts point to revised assumptions for margins and future P/E, along with broadly steady growth expectations, as key drivers of the change.Aggiornamento della narrazione • Mar 04
LAURUSLABS: Steady Fair Value And Solid Fundamentals Will Support Upside
Analysts have kept their price target for Laurus Labs steady at ₹1,280, reflecting small adjustments to assumptions on discount rate, revenue growth, profit margin and future P/E. These changes are consistent with recent Street research, where targets shifted within a relatively tight range and analysts cited solid fundamentals alongside mixed near term signals.
Aggiornamento della narrazione • Feb 18
LAURUSLABS: Future Returns Will Rely On Confidence In Elevated P E Assumptions
Narrative Update: Laurus Labs Analyst Price Target Analysts have maintained their Laurus Labs price target at ₹913.47, citing largely unchanged assumptions around revenue, profit margins, discount rate, and forward P/E as the basis for keeping fair value steady. Analyst Commentary Analysts covering Laurus Labs are using a similar playbook to recent work on other education and healthcare names, where price targets are adjusted mainly on valuation inputs rather than big changes in growth assumptions.Aggiornamento della narrazione • Feb 03
LAURUSLABS: Future Returns Will Depend On Confidence In Rich P E Assumptions
Analysts have lifted their fair value estimate for Laurus Labs from ₹863.13 to ₹913.47, citing slightly higher assumptions for revenue growth, profit margins and future P/E multiples, consistent with recent upward target revisions seen in related Street research. Analyst Commentary Bullish analysts point to the higher fair value estimate of ₹913.47 as support for a more constructive view on Laurus Labs, even though inputs are only slightly adjusted.Articolo di analisi • Jan 28
Results: Laurus Labs Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Laurus Labs Limited ( NSE:LAURUSLABS ) just released its quarterly report and things are looking bullish. It was...Articolo di analisi • Jan 25
Laurus Labs Limited's (NSE:LAURUSLABS) Popularity With Investors Is Under Threat From Overpricing
With a price-to-earnings (or "P/E") ratio of 65.1x Laurus Labs Limited ( NSE:LAURUSLABS ) may be sending very bearish...Aggiornamento della narrazione • Jan 20
LAURUSLABS: Future Returns Will Depend On Rich P E Assumptions Holding
Analysts have lifted their price target for Laurus Labs to ₹863 from about ₹822, reflecting updated assumptions on fair value, profit margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target as a sign that current assumptions on Laurus Labs' fair value leave room for upside if the company executes consistently on profitability.Aggiornamento della narrazione • Jan 06
LAURUSLABS: Interim Dividend And Higher P E Multiple Will Support Upside
Analysts have raised their price target on Laurus Labs from ₹1,025 to ₹1,280, citing updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News The Board of Directors approved an interim dividend of ₹0.80 per equity share of face value ₹2 for the 2025-26 financial year at the meeting held on October 23, 2025 (company filing).Aggiornamento della narrazione • Dec 21
LAURUSLABS: Interim Dividend May Not Offset Softer Margins Ahead
Analysts have moderately raised their price target on Laurus Labs from ₹303.09 to ₹330.21, citing a slightly higher justified valuation multiple that more than offsets their marginally softer assumptions on revenue growth and profit margins. What's in the News The Board approved an interim dividend of INR 0.80 per equity share (40 percent of the face value of INR 2) for FY 2025-26, signaling confidence in cash flows and shareholder returns (company filing).Aggiornamento della narrazione • Dec 07
LAURUSLABS: Future Returns Will Likely Hinge On Managing Execution Risks
Analysts have modestly increased their price target for Laurus Labs while maintaining fair value at ₹821.93, citing expectations of sustained earnings growth supported by a solid balance sheet, margin expansion, and revenue momentum from new market opportunities. Analyst Commentary Street research on comparable growth stories in the education and healthcare sectors highlights themes that are directly relevant for Laurus Labs, particularly around how markets price in multi year earnings expansion, balance sheet strength, and scalability in new markets.Aggiornamento della narrazione • Nov 23
LAURUSLABS: Future Revenue Upside May Be Limited By Execution Risks
Analysts have raised their price target for Laurus Labs slightly, from ₹815.86 to ₹821.93. They cite expectations of stronger revenue growth supported by a robust balance sheet and expanding opportunities in new markets.Aggiornamento della narrazione • Nov 04
LAURUSLABS: Margin Pressures From Rising Input Costs Will Weigh On Earnings
Analysts have raised their fair value price target for Laurus Labs from ₹724.14 to ₹815.86. They cite increased profitability outlook and sustained margin growth as key drivers for the revision.Articolo di analisi • Oct 30
Laurus Labs' (NSE:LAURUSLABS) Dividend Will Be ₹0.80
Laurus Labs Limited ( NSE:LAURUSLABS ) will pay a dividend of ₹0.80 on the 22nd of November. Even though the dividend...Aggiornamento della narrazione • Oct 21
Analysts Cite Growth Momentum and Strong Balance Sheet in Raising Laurus Labs Valuation Estimates
Analysts have raised their fair value estimate for Laurus Labs from ₹694.85 to ₹724.14. They cite continued revenue growth momentum and a strong balance sheet as key drivers for this upward revision.Articolo di analisi • Oct 19
With Laurus Labs Limited (NSE:LAURUSLABS) It Looks Like You'll Get What You Pay For
Laurus Labs Limited's ( NSE:LAURUSLABS ) price-to-sales (or "P/S") ratio of 8.2x may look like a poor investment...Articolo di analisi • Aug 31
Laurus Labs (NSE:LAURUSLABS) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jul 20
Revenues Tell The Story For Laurus Labs Limited (NSE:LAURUSLABS) As Its Stock Soars 28%
The Laurus Labs Limited ( NSE:LAURUSLABS ) share price has done very well over the last month, posting an excellent...Articolo di analisi • Jun 11
Investors Shouldn't Be Too Comfortable With Laurus Labs' (NSE:LAURUSLABS) Earnings
Unsurprisingly, Laurus Labs Limited's ( NSE:LAURUSLABS ) stock price was strong on the back of its healthy earnings...
Nuova narrazione • Jan 26
CDMO Expansion May Impact Near-Term Margins But Pave Way For Future Revenue Streams
Heavy investment in CDMO and microbial precision initiatives may lead to revenue delays and short-term margin compression due to underutilized assets.Rendimenti per gli azionisti
| LAURUSLABS | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 2.7% | 3.7% | 0.5% |
| 1Y | 128.7% | 10.5% | -0.7% |
Ritorno vs Industria: LAURUSLABS ha superato il Indian Pharmaceuticals che ha restituito 10.5 % nell'ultimo anno.
Rendimento vs Mercato: LAURUSLABS ha superato il mercato Indian che ha restituito -0.7 % nell'ultimo anno.
Volatilità dei prezzi
| LAURUSLABS volatility | |
|---|---|
| LAURUSLABS Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.8% |
Prezzo delle azioni stabile: LAURUSLABS non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di LAURUSLABS è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2005 | 6,167 | Satyanarayana Chava | www.lauruslabs.com |
Laurus Labs Limited, insieme alle sue controllate, produce e vende farmaci e ingredienti farmaceutici attivi (API) in India e a livello internazionale. L'azienda offre API generici per intermedi avanzati per le aree terapeutiche antiretrovirale (ARV), antidiabetica, cardiovascolare, antiasmatica, oftalmologica, oncologica, gastroenterologica e dell'epatite C. Fornisce anche formulazioni solide orali per ARV, antidiabetici, cardiovascolari e IPP. Inoltre, l'azienda offre servizi organizzativi di sviluppo e produzione a contratto e servizi di biotecnologia utilizzati per prodotti nutraceutici, integratori alimentari, proteine alimentari alternative e cosmeceutici.
Laurus Labs Limited Riepilogo dei fondamenti
| LAURUSLABS statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹729.35b |
| Utili (TTM) | ₹8.89b |
| Ricavi(TTM) | ₹68.13b |
82.1x
Rapporto P/E10.7x
Rapporto P/SLAURUSLABS è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| LAURUSLABS Conto economico (TTM) | |
|---|---|
| Ricavi | ₹68.13b |
| Costo del fatturato | ₹26.95b |
| Profitto lordo | ₹41.17b |
| Altre spese | ₹32.29b |
| Utili | ₹8.89b |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 16.46 |
| Margine lordo | 60.44% |
| Margine di profitto netto | 13.05% |
| Rapporto debito/patrimonio netto | 44.1% |
Come si è comportato LAURUSLABS nel lungo periodo?
Vedi performance storica e confrontoDividendi
0.2%
Rendimento attuale del dividendo12%
Rapporto di remunerazioneLAURUSLABS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LAURUSLABS| Laurus Labs date dei dividendi | |
|---|---|
| Data di stacco del dividendo | May 08 2026 |
| Data di pagamento dei dividendi | May 30 2026 |
| Giorni fino al dividendo Ex | 14 days |
| Giorni prima della data di pagamento dei dividendi | 8 days |
LAURUSLABS paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di LAURUSLABSAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/21 22:09 |
| Prezzo dell'azione a fine giornata | 2026/05/21 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Laurus Labs Limited è coperta da 22 analisti. 14 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Ashwin Mehta | Ambit Capital |
| null null | Antique Stockbroking Ltd. |